Markets:

Overview

News

Currencies

International

Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

1.188 +0.177 (+17.57%)

Streaming Delayed Price Updated: 3:18 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants ↗

November 19, 2025

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.

Via Benzinga

Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 21, 2025

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

May 30, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 30, 2025

Via Benzinga

Top movers in Friday's session ↗

May 30, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Traders are paying attention to the gapping stocks in Friday's session. ↗

May 30, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

May 29, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled ↗

May 29, 2025

AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.

Via Stocktwits

Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone ↗

May 29, 2025

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.

Via Benzinga

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 29, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 29, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

The market is filled with gapping stocks in Thursday's session. ↗

May 29, 2025

Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue ↗

May 29, 2025

Via Benzinga

What's going on in today's pre-market session ↗

May 29, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

May 13, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants ↗

May 13, 2025

Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Friday? ↗

May 09, 2025

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program ↗

May 07, 2025

Alzamend Neuro teams up with QMENTA for five AL001 Phase 2 trials at Mass General, targeting Alzheimer's, PTSD, bipolar disorder, and more.

Via Benzinga

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits ↗

March 11, 2025

Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and reduced systemic side effects.

Via Benzinga

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 ↗

February 25, 2025

Alzamend Neuro will begin its first Phase 2 trial of AL001 in 2025, using advanced imaging to study lithium distribution and optimize treatment efficacy.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

February 19, 2025

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels ↗

February 19, 2025

Alzamend Neuro developed a head coil for high-resolution brain imaging in Phase 2 trials, aiming to optimize lithium dosing for neurological conditions.

Via Benzinga

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential ↗

November 19, 2024

Alzamend Neuro's AL001 study highlights safety and therapeutic potential for Alzheimer's and psychiatric conditions, reducing systemic side effects.

Via Benzinga

EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's ↗

October 16, 2024

Alzamend Neuro completed a Phase 2A study on AL001, identifying a safe lithium dose for Alzheimer's patients. The company plans further trials comparing brain lithium levels in Alzheimer's and other...

Via Benzinga

Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗

August 20, 2024

Via Benzinga

Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

August 19, 2024

On Monday, major U.S. indices closed in positive territory. The Dow Jones Industrial Average rose 0.6% to finish at 40,896.53.

Via Benzinga

Topics Stocks

Nasdaq Surges 150 Points; Sonder Holdings Shares Surge ↗

August 19, 2024

Via Benzinga

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 19, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

Headline News about Alzamend Neuro, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today